ANAVEX LIFE SCIENCES CORP. Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect
ANAVEX LIFE SCIENCES CORP. (AVXL) reported Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect of $15.75 million for the 9-month period ending 2026-06-30, per its 10-Q filed 2026-08-28.
Financial Statements › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect · last filed 2026-08-28
- ANAVEX LIFE SCIENCES CORP. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2025-12-31 was $29.17M.
- ANAVEX LIFE SCIENCES CORP. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2024-12-31 was -$11.41M.
- ANAVEX LIFE SCIENCES CORP. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2023-12-31 was -$7.26M.
- ANAVEX LIFE SCIENCES CORP. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2022-12-31 was -$5.54M.
- ANAVEX LIFE SCIENCES CORP. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2025 was -$29.61M.
- ANAVEX LIFE SCIENCES CORP. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2024 was -$18.84M, a 1109.49% decline from fiscal 2023.
- ANAVEX LIFE SCIENCES CORP. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2023 was $1.87M.
- ANAVEX LIFE SCIENCES CORP. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2022 was -$2.95M, a 102.40% decline from fiscal 2021.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 3 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 3 month as first filed | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 6 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 6 month as first filed | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 9 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 9 month as first filed | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 12 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $15.75M 10-Q · filed 2026-08-28 | |||||||
| 2026-03-31 | $24.84M 10-Q · filed 2026-08-28 | |||||||
| 2025-12-31 | $29.17M 10-Q · filed 2026-02-09 | |||||||
| 2025-09-30 | -$29.61M 10-K/A · filed 2026-08-28 | |||||||
| 2025-06-30 | -$31.02M 10-Q · filed 2026-08-28 | |||||||
| 2025-03-31 | -$16.42M 10-Q · filed 2026-08-28 | |||||||
| 2024-12-31 | -$11.41M 10-Q · filed 2026-02-09 | |||||||
| 2024-09-30 | -$18.84M 10-K/A · filed 2026-08-28 | |||||||
| 2024-06-30 | -$12.27M 10-Q · filed 2025-08-12 | |||||||
| 2024-03-31 | -$11.64M 10-Q · filed 2025-05-13 | |||||||
| 2023-12-31 | -$7.26M 10-Q · filed 2025-02-12 | |||||||
| 2023-09-30 | $1.87M 10-K/A · filed 2026-08-28 | |||||||
| 2023-06-30 | $5.66M 10-Q · filed 2024-08-06 | $5.66M 10-Q · filed 2023-08-08 | ||||||
| 2023-03-31 | $4.31M 10-Q · filed 2024-05-09 | $4.31M 10-Q · filed 2023-05-09 | ||||||
| 2022-12-31 | -$5.54M 10-Q · filed 2024-02-07 | -$5.54M 10-Q · filed 2023-02-07 | ||||||
| 2022-09-30 | -$2.95M 10-K · filed 2023-11-27 | -$2.95M 10-K · filed 2022-11-28 | ||||||
| 2022-06-30 | $1.09M 10-Q · filed 2023-08-08 | |||||||
| 2022-03-31 | $1.23M 10-Q · filed 2023-05-09 | |||||||
| 2021-12-31 | -$961.39K 10-Q · filed 2023-02-07 | |||||||
| 2021-09-30 | $122.86M 10-K · filed 2023-11-27 | $122.86M 10-K · filed 2021-11-24 | ||||||
| 2021-06-30 | $128.31M 10-Q · filed 2022-08-09 | |||||||
| 2021-03-31 | $46.61M 10-Q · filed 2022-05-10 | |||||||
| 2020-12-31 | $18.11M 10-Q · filed 2022-02-09 | |||||||
| 2020-09-30 | $7.06M 10-K · filed 2022-11-28 | |||||||
| 2020-06-30 | $5.43M 10-Q · filed 2021-08-12 | |||||||
| 2020-03-31 | $4.38M 10-Q · filed 2021-05-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 | |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| Protara Therapeutics, Inc. (TARA) | United States | $0.198B | -3.22 |
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |
| Alpha Cognition Inc. (ACOG) | $0.185B | -6.77 | |
| Coherus Oncology, Inc. (CHRS) | United States | $0.182B | -1.63 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| PRECISION BIOSCIENCES INC (DTIL) | United States | $0.175B | -3.95 |